We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Emergent Biosolutions (EBS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of EBS and the rest of the Medical group's stocks.
Emergent Biosolutions is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank of #13. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. EBS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for EBS's full-year earnings has moved 56.34% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that EBS has returned about 79.26% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -0.45% on a year-to-date basis. This shows that Emergent Biosolutions is outperforming its peers so far this year.
Looking more specifically, EBS belongs to the Medical - Biomedical and Genetics industry, which includes 414 individual stocks and currently sits at #180 in the Zacks Industry Rank. On average, stocks in this group have lost 1.66% this year, meaning that EBS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track EBS. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Emergent Biosolutions (EBS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of EBS and the rest of the Medical group's stocks.
Emergent Biosolutions is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank of #13. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. EBS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for EBS's full-year earnings has moved 56.34% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that EBS has returned about 79.26% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -0.45% on a year-to-date basis. This shows that Emergent Biosolutions is outperforming its peers so far this year.
Looking more specifically, EBS belongs to the Medical - Biomedical and Genetics industry, which includes 414 individual stocks and currently sits at #180 in the Zacks Industry Rank. On average, stocks in this group have lost 1.66% this year, meaning that EBS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track EBS. The stock will be looking to continue its solid performance.